Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Version history
  • Article usage
  • Citations to this article

Advertisement

News Free access | 10.1172/JCI26055

New Annie and Willie Nelson Professor says award is music to his ears

Stacie Bloom

Find articles by Bloom, S. in: PubMed | Google Scholar

Published August 1, 2005 - More info

Published in Volume 115, Issue 8 on August 1, 2005
J Clin Invest. 2005;115(8):1967–1968. https://doi.org/10.1172/JCI26055.
© 2005 The American Society for Clinical Investigation
Published August 1, 2005 - Version history
View PDF

In March, singer Willie Nelson and his wife, Annie, put on a benefit concert to raise funds for a stem cell program at The University of Texas Southwestern Medical Center at Dallas. The concert raised $250,000, which was used to create a professorship named for Annie and Willie Nelson. The first Nelson Professor is Eric Olson, chairman of the Department of Molecular Biology. The JCI spoke with Olson about the award, his career, and his musical inclinations.

JCI: How were you selected for this award?

Olson: As a developmental biologist, I have a natural interest in stem cell biology, and my lab has initiated some interesting projects on the control of stem cell fates. Second, I love country music, and I think I’m a bigger fan of the genre than any of my colleagues. Since I love Texas and country music and Willie Nelson is an icon of both, being named the Willie Nelson Professor is about as cool as it gets.

JCI: What will this prize money be used for?

Olson: The intention is to enhance the UT Southwestern stem cell program in general, not just my lab. I expect we will use the funds to purchase equipment, support core facilities, and catalyze new projects not yet ready for NIH support.

JCI: Tell us about the research your lab does.

Olson: My lab uses muscle cells as a model to understand the basic mechanisms of development and differentiation. Understanding how a stem cell becomes a specialized cell is a holy grail for developmental biologists. Recently, we’ve come up with some interesting ideas about how to discover small molecules that may influence the behavior of stem cells as well as [ideas about] how epigenetic mechanisms may participate in stem cell decisions.

JCI: Where do you stand on the controversies surrounding stem cell research?

Olson: I certainly believe embryonic stem cells have great potential in regenerative medicine. But right now, it’s mostly just potential. A lot of groundwork needs to be laid. Regarding the ethical issues, I will say that I have solid religious beliefs and try to attend church regularly with my family. In that context, I do not believe stem cells equal human life, and I do not accept the position that using human stem cells to improve human life is unethical. On the contrary, it seems unethical to arbitrarily deny therapies that could potentially improve the human condition. The fact is that if and when embryonic stem cells are shown to cure diabetes or Parkinson’s or spinal cord injury — pick your disorder — then the demand will be so great that no politician will be able to stand in the way. In the meantime, there is a lot of interesting science to do.

JCI: What do you consider your greatest scientific accomplishment?

Olson: The greatest accomplishment has been the discovery of numerous master regulators of muscle development. Over the past 20 years, we have discovered many transcription factors that control the fate, differentiation, and patterning of cardiac, skeletal, and smooth muscle cells. We have delineated evolutionarily conserved pathways that control muscle gene expression during development and disease. The realization that many developmental regulatory mechanisms are also deployed in the adult heart during pathological remodeling kindled my interest in [exploiting] our understanding of muscle development to develop novel drugs to treat cardiovascular diseases. Several years ago, I cofounded Myogen Inc., which [translates] basic science into drugs. This has allowed me to do something practical with the science from my lab.

JCI: Can you describe your typical day?

Olson: I’m up by 6:00 a.m. and usually deal with mail from the day before, e-mails, and administrative paperwork before dropping one or more of my three kids off at school on the way to the lab. The first thing I do when I get to work is make the rounds looking for results someone may have generated the night before. Most of my day is spent talking with students and postdocs and working on papers. As a department chair, I also have administrative responsibilities, but I have a great staff that carries much of that load. I usually leave the lab by 6:00 p.m. to either drive kids in car pool or work out and get home in time for dinner with the family.

JCI: Are you a fan of country music?

Olson: I am indeed a fan of country music and have attended many Willie Nelson concerts. I also love the blues and rock and roll. In my spare time, what little there is, I play guitar and harmonica in a group called the Transactivators with friends from my department. Inspired by the Willie Nelson Professorship, we are working on a new tune called “Mama, don’t let your stem cells grow up to be cowboys”.

JCI: At the end of your career, what do you hope to have accomplished?

Olson: My long-term goals are to create a blueprint for development of cardiac, skeletal, and smooth muscle cells and to use that knowledge to improve human health. Along the way, I hope to populate the field with outstanding, independent trainees and the next generation of scientific leaders.

Version history
  • Version 1 (August 1, 2005): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts